Similar efficacy was observed with high-dose IL-2 treatment for metastatic melanoma, where 16% of patients (270 patients total) had an objective response with 17 patients having a complete response and 26 patients experiencing a partial response (210). This evidence concerns the gene IL2 and metastatic melanoma.